Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 11/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 9/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17069027 | 0.81 | ALDH1A1 (0.45) | ENPP2ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL16400185 | 0.77 | ALDH1A1 (0.42) | ENPP2ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL16949042 | 0.75 | SPHK2 (0.53) | SPHK2SPHK1 | |
| SCHEMBL17069030 | 0.75 | ALDH1A1 (0.67) | ALDH1A1 | |
| SCHEMBL16945609 | 0.74 | CHRM2 (0.47) | — | |
| SCHEMBL16945703 | 0.72 | SPHK2 (0.53) | SPHK2SPHK1 | |
| SCHEMBL16949598 | 0.72 | SPHK2 (0.53) | SPHK2SPHK1 | |
| SCHEMBL14213479 | 0.71 | OGA (0.37) | ENPP2ALDH1A1 | |
| SCHEMBL14213477 | 0.71 | OGA (0.37) | ENPP2ALDH1A1 | |
| SCHEMBL14213466 | 0.71 | OGA (0.37) | ENPP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688668-B2 | Long chain base sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688668-B2 | Long chain base sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150210675-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2015-07-30 | — | — | US | disclosed |
| US-20150210675-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210675-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | SPHK1, SPHK2, SGPL1 | SPHK2 2/4885SPHK1 1/4885ENPP2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.